Tumor in Biological Technology

Viral Genetics Creates Subsidiary to Develop Cancer Therapy

... technology" (MDT), which focuses on blocking a tumor cell's ability to generate energy from glucose or ... radiation therapy to further limit the growth of tumor cells. Dr. Richard J. Trauger, Ph. D., will be ... on the cutting edge of metabolic disruption of tumor cells for many years helped develop the process ...

OncoGenex Reports Second Quarter 2009 Financial Results

... demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... specifically targets cancer stem cells, a type of tumor cell responsible for driving tumor initiation, growth and recurrence. Research ... blocking a key cancer stem cell pathway impacts tumor cell proliferation, growth and recurrence." ...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

... and its suppression has been shown to decrease tumor size and improve hearing in some patients with ... inhibitor improved hearing and led to tumor shrinkage in some patients," said Scott R. ... of the study is to assess how PTC299 affects tumor volume and changes in hearing and word ...

Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting

... information about the probability of achieving tumor control alongside the risk of damaging healthy ... a single treatment plan for treating a large tumor and then deliver the treatment in one operation, rather than treating one small portion of the tumor at a time. Varian's AAPM ...

Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing

... development of advanced preclinical platforms and tumor specific data to enhance the value of oncology ... development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value ... offers its predictive preclinical platform and tumor specific data to physicians for personalized ...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

... blocking, and modifying protein kinase triggered tumor cell metabolism, proliferation, and DNA damage. ... combination drug therapies. Growing incidences of tumor cell resistance to single targeted kinase ... against cancer can be horned not by blocking out tumor cells at one point, but by simultaneously ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... Greater Than 300-Fold More Radiation Delivered to tumor as Compared to Other Normal Organs - - All ... found that Cotara was concentrated in the brain tumor with minimal exposure to the contralateral ... sites for radiation toxicity. On average, the tumor received more than 300 times the dose of ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... were followed up to determine the time to tumor recurrence or progression in the area that had ... that the addition of perifosine would sensitize tumor cells to the tumor-killing effect of the ... to loco-regional or distant/systemic failure, the tumor response rate, and overall survival. Safety ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.

... to deliver a potent, cell-killing agent to tumor sites while avoiding toxicity in healthy, ... candidate, G-202, is designed to attack existing tumor vasculature, potentially debilitating the tumor's ... to enzymes believed to be found solely at a tumor location. G-115, GenSpera's primary candidate ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... Data from Phase II Study Shows 71% Objective tumor Response Rate in Evaluable Patients Receiving ... first cohort of the trial achieved an objective tumor response by the end of the treatment period ... specifically on the outside of cells that line tumor blood vessels. Once bound to the exposed PS, ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... of AT-101 is being explored in several major tumor types and treatment regimens, with prostate ... responses per RECIST. A reduction in circulating tumor cells was also reported after the first cycle of ... for cancer cells to undergo apoptosis in various tumor types. About Ascenta Therapeutics ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... drug to discriminate between healthy cells and tumor cells," said David Allan, Chairman and CEO of YM ... it to target the higher density of EGFR found in tumor cells while avoiding the lower density of EGFR in ... and gut. In the clinical setting, where the tumor cells rely on the EGFR pathway to repair ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Orange, CA Circulating tumor cells (CTC) in a study of relapsed/recurrent ... Thromboembolic Events, and increased risk of tumor progression OR recurrence Renal failure: ... overall survival and/or increased the risk of tumor progression or recurrence in some clinical ...

Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting

... Phase I Study Evaluating Bavituximab in Multiple tumor Types - TUSTIN, Calif., May 27 ... mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two ...

Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology

... treatments were designed to narrowly target his tumor while avoiding, as much as possible, the delicate ... X-ray image-guidance technology to adjust for any tumor movement due to Bickford's breathing during ... It enabled us to verify the position of the tumor prior to each treatment and deliver the dose in a ...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

... 2, West Hall C) Gastrointestinal Stromal tumor (GIST) Sunday, May 31 st , 2009: ... with imatinib-resistant gastrointestinal stromal tumor (GIST). Lead Author: Anthony Conley, MD ... Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... was well tolerated. Declines in circulating tumor cells (CTCs), an emerging metric to assess ... have been observed at all dose levels. Changes in tumor markers (i.e declines of PSA, CA-125) have also been observed. Reductions in CTCs and tumor markers both suggest single-agent activity. The ...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

... to explore the potential of Nexavar in other tumor types with several studies being presented at ... Joaquim Bellmunt, M.D., Chief of the Solid tumor Oncology Section, Medical Oncology Service, ... Mechanism Nexavar targets both the tumor cell ...

First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418

... by downregulating several pivotal oncogenic and tumor survival pathways. The Phase I study is led ... molecule to treat cancer in many different tumor types." "We are excited to participate in ... by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid ...

Telik Reports Preclinical Results at AACR Annual Meeting

... checkpoints. More than 80% inhibition of tumor growth was seen in an HL60 xenograft model ... inhibition of aurora kinase and VEGFR activity in tumor samples of treated animals was established by ... growth of nine established cell lines of various tumor types and retained its effectiveness against ...

Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial

... Carboplatin + Paclitaxel Achieved an Objective tumor Response - - Patient Dosing Underway in ... in the initial cohort achieved an objective tumor response after a maximum of six treatment cycles ... "We are pleased to see these additional objective tumor responses in these advanced breast cancer ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... direct the body's cell-destroying T cells against tumor cells. MT110 recognizes cancer cells expressing ... expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show ... stem cells, resulting in a complete inhibition of tumor growth and survival, while untreated animals with ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical ... led to significant increases in neuroblastoma tumor bearing mouse survival. In summary, ... cells and xenografts, and significantly inhibits tumor growth. Abstract 4794: Targeting breast ...

Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells

... designed to restore normal gene function to tumor cells while completely bypassing normal tissue ... is able to locate primary and hidden metastatic tumor cells and deliver its payload: a fully functioning copy of the P53 tumor suppressor gene. Normal cells have two copies ...

VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

... near-infrared imaging agent to measure tumor MMP activity in vivo and monitor treatment ... FMT 2500 (TM) quantitative tomography system, tumor fluorescence due to in vivo activation of the ... activity, which was closely associated with tumor progression", said Dr. Peterson. Both of the ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... and angiopoietin-2 inhibitors on tumor blood vessels and normalization Overview: ... of Angiopoietin (Ang) 1 and Ang2 on the tumor vasculature of a human colon carcinoma model ... reduce tumor-associated macrophages and decrease tumor growth in preclinical models ...

Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business

... development of advanced preclinical platforms and tumor specific data to enhance the value of oncology ... of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value ... offers its predictive preclinical platform and tumor specific data to physicians for personalized ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... R. et al. (2009). Potent control of tumor growth by CEA/CD3- bispecific single-chain ... cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach ... a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting ...

Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer

... of the trial, and progression free survival and tumor response rates will be compared as secondary ... Nereus is also evaluating NPI-2358 in other solid tumor indications and expects to initiate additional ... a newer class of agents that selectively attack tumor vasculature like anti-angiogenesis agents, but ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... and Chief of the Laboratory of Molecular and tumor Immunology at the Robert W. Franz Cancer Research ... Health and Science University (OHSU), and Leader, tumor Immunology Focus Panel, OHSU Knight Cancer ... a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting ...

Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results

... development of advanced preclinical platforms and tumor specific data to enhance the value of oncology ... through additional collaborations to acquire tumor samples and by implanting, propagating and ... of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value ...

FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418

... by downregulating several pivotal oncogenic and tumor survival pathways. "We are excited to reach ... by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid ... and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce ...

New Study Reports Improved Patient Outcomes for Breast Cancer Patients

... known to influence outcomes. "These include tumor and patient characteristics, completeness of local surgical tumor excision, and adjuvant radiation therapy and/or ... Robert Zimmerman, M.D., along with Brian Cooper, tumor registrar officer. ABOUT HENRY MAYO - ...

Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer

... in an excellent review** on the impact of tumor gene expression profiling outcomes in patients ... concerned by the lack of direct evidence linking tumor gene expression profiling to improved outcomes. ... Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests ...

Tigris Pharmaceuticals Files IND Application for GGTI-2418

... by downregulating several pivotal oncogenic and tumor survival pathways. "The filing of this IND ... by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid ... and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce ...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study

... of 17 Evaluable Patients Achieved an Objective tumor Response by End of Four Treatment Cycles- ... enrolled in Stage A were deemed evaluable for tumor response by the end of four treatment cycles, with six patients achieving partial tumor responses and one patient achieving a ...

AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences

... small molecule candidate drug AGX51 to mitigate tumor formation and metastases. Dr. Robert ... results in a highly significant inhibition of tumor growth and a reduction in the size of mature ... of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its ...

Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience

... and his associated authors obtained high rates of tumor control, even for large lesions and lesions near ... near sensitive structures, obtain excellent tumor control, and keep neurological complications to ... automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the ...